COVID-19: Everything you need to know about the virus and the different variants!
Published 1 Jun 2021 • By Aurélien De Biagi
To shed some light on this complex subject, we thought we would share an article with you on COVID-19 and its different variants.
What is a variant? How are the COVID-19 variants different from each other?
We explain it all in our article!
Viruses, in general, are infectious agents that must penetrate a cell in order to replicate. Although they all share this characteristic, there are many differences between each family. For example, there are enveloped viruses and naked viruses, DNA viruses and RNA viruses, etc. However, all of these viruses all infect their target cell and divert the latter's processes towards the production of new viruses, called virions.
How does the COVID-19 virus function?
The SARS-CoV-2 virus, responsible for COVID-19 (coronavirus disease 2019), belongs to the beta group of the coronavirus family. The latter is also responsible for other epidemics that occurred in Asia in 2003 (SARS-COV-1 epidemic) and 2012 (MERS).
SARS-CoV-2 is an enveloped virus, meaning that it has an envelope (of cellular origin) surrounding its genetic material. The genetic material consists of a single positive strand of RNA. This means that when the virus infects a cell, its RNA strand can be directly translated into protein by the cellular machinery. As a result, the cell can no longer perform its physiological functions (due to the production of viral proteins) which, among other things, causes the problems associated with the disease.
The genome of this virus codes for 20 proteins, 16 of which are non-structural proteins that allow the hijacking of the cellular machinery, the production and maturation of viral RNA.
The remaining 4 proteins are structural. There are the E and M proteins, for "envelope" and "membrane" respectively, the N nucleoprotein which protects the viral RNA and finally the S protein for "Spike". The E, M and S proteins form the envelope.
It is also thanks to a protein that this virus penetrates cells. Indeed, the S protein allows, via its binding to a receptor (ACE2), the penetration of the virus inside the host cell. Indeed, after the ligand binds to its receptor, the cell membrane internalises the virus in an endosome which then releases the virus' RNA.
These ACE2 receptors are found in lung, kidney, liver, heart and intestinal cells, which explains the many different types of SARS-CoV-2 symptoms (digestive and heart problems, kidney failure, shortness of breath, etc.). Furthermore, ACE2 has many similarities with the nicotinic acetylcholine receptor found in the nervous system. This could explain the neurological symptoms of the disease such as anosmia (loss of smell) and agueusia (loss of taste).
Why are there variants of COVID-19?
The variants are due to mutations in the virus genome. All viruses mutate. Indeed, during each reproduction mutations appear, there are substitutions, insertions, deletions and duplications. However, the vast majority of these mutations have no effect.
In the case of SARS-CoV-2, the mutations that cause the variants affect the S protein. The S protein is not only responsible for virus internalisation, but is also the target of natural or vaccine immunity. Today, there are nearly 4000 mutations in the Spike protein. A virus whose mutation modifies an important characteristic of the virus (severity, symptoms, ability to infect, etc.) is called a "variant".
There are currently 4 different variants: UK, South African, Brazil and California.
What are the differences between the variants?
The UK variant
The UK variant has 19 notable mutations, 8 of which are in the S protein. Among them, the N501Y mutation slightly modifies the tip of the protein, thus facilitating its binding with its ACE2 receptor. It therefore allows the virus to be more easily transmissible. However, a recent Harvard study appears to show that the increased transmissibility of this variant could be due to a higher viral load during infection.
A second notable mutation is the P681H mutation which is thought to increase the production of S protein.
The vaccines currently on the market are thought to provide sufficient protection against this variant.
The vast majority of new cases in the UK are caused by this variant at present.
The South Africa variant
This variant has 13 main mutations, 8 of which are on the S protein. These include N501Y again, but also K417N. The latter mutation is thought to have the same effects as N501Y (increased transmissibility). We also note the appearance of the E484K mutation. This mutation also modifies the S protein, but this time the consequence is a potential ability to get around some of the protection offered by natural and vaccine immune responses. Indeed, according to studies, the Novavax and Johnson & Johnson vaccines have shown lower efficiency in South Africa.
In contrast, the neutralising capacity of the mRNA vaccines (Pfizer and Moderna) is only reduced by 30%. According to immunologists, this reduction should not have any consequences because of the high initial protection rate of mRNA vaccines (over 90%).
As of 19 May 2021, there are only 904 confirmed cases of this variant (808 of which are in England) in the UK. There is no evidence of increased mortality from this virus. Concerns are now focused on resistance to immunity, in particular that provided by a previous infection with COVID-19.
The Brazil variant
This variant is very similar to the South African variant. It has the mutations N501Y and K417T (close to K417N) which promote transmission and E484K which amplifies resistance to immunity. Although the degree of resistance to natural and vaccine immunity is not clearly known, it appears to be similar to that of the South African variant.
As of 19 May, there are only 60 confirmed cases of the Brazilian variant in the UK, 54 of which are in England.
The California variant
This variant carries the L452R mutation on the S protein, which is thought to facilitate its transmission. Having first been observed in Denmark in fall of 2020, by January 2021, this variant made up 35% of all cases in the state and 44% of all cases in Southern California. In recent weeks it has been overtaken by the UK variant once again.
Its prevalence in the UK is not known.
In summary, there are many mutations in the virus that causes COVID-19. Some of them could limit the effectiveness of vaccines, although nothing is certain at the moment. The more a virus circulates, the more it will mutate. It is therefore important to limit its circulation. This is where vaccines come in.
Was this article helpful to you?
Share your thoughts and questions in the comments below!
- COVID-19 : maladie, virus et traitement, Institut de France académie des sciences
- COVID-19 : mutations, variants, lignées, N501Y, E484K… de quoi parle-t-on ?, Vidal
- Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2, Harvard Library
- Xenothera annonce l’efficacité de XAV-19, son traitement anti-Covid, contre les variants du SARS-CoV-2, My pharma édition
- Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19), Clinical trials.gov
- Covid : Novavax devrait livrer son vaccin à l'Europe dès fin 2021, Les Echos
- Une Biotech indienne publie de bons résultats sur son Vaccin COVID-19. La France livrée en priorité?, Biotech bourse
- Présentation faite par Lauriane Armand et Alizé Vivès